Scribe Therapeutics Inc. logo

Scribe Therapeutics Inc.

SCTX

NASDAQHealthcareBiotechnology

Previous close

$34.13

+$1.30 · +3.96%

Aug 21, 4:00 PM ET

Pre-market

$35.25

+$1.12 · +3.28%

Aug 24, 7:32 AM ET

SCTX company overview

Regular session · ET · Market data may be delayed.

Company profile

Company website

Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Benjamin L. Oakes
Listed since
Jul 24, 2026
Employees
89

Market position

Day range

Current $34.13

52-week range

Current $34.13

Open
$33.90
Previous close
$32.83
Volume
179.58K
0.73× average
Average volume
245.4K
Average daily volume
Market cap
552.29M USD
Beta
0
Market reference 1
50-day average
$23.6085
+44.57% above average
200-day average
$23.6085
+44.57% above average

SCTX peers

ETFs holding SCTX

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research SCTX

research.disclaimer